NCT05633654
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT05633654 ↗
- Recruiting
- Gilead Sciences
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT05633654 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05633654 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Sacituzumab govitecan-hziy (SG); Pembrolizumab; Capecitabine
- Arms
- Sacituzumab govitecan-hziy (SG) + Pembrolizumab · Experimental
- Treatment of Physician's Choice (TPC): Pembrolizumab or Pembrolizumab + Capecitabine · Active comparator
- Enrollment
- 1,514 (estimated)
- Primary outcomes
- Invasive Disease-free Survival (iDFS)
- Sponsor
- Gilead Sciences with Alliance Foundation Trials, LLC., NSABP Foundation Inc, GBG Forschungs GmbH
- Start
- Dec 12, 2022
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05633654 · updated Nov 4, 2026
Publications
linked from the registry- Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (+/- capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26. PubMed 38922307